In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zydus Of India, Teva Of Israel Settle Two Generics Disputes

This article was originally published in PharmAsia News

Executive Summary

India's ZydusCadila and Israel's Teva have reached a settlement of generics makers over a patent dispute involving the active pharmaceutical ingredients of multinational company antipsychotic drugs. Zydus and Teva had squabbled over competing generics to be marketed in the United States, but the settlement allows Zydus to sell its versions without facing a legal challenge by Teva. The API at issue is carvedilol, used in GlaxoSmithKline's Coreg, which lost its patent protection last year. Zydus had sued Teva over a generic of Johnson & Johnson's Risperdol (risperidone), accusing the Israeli company of antitrust and deceptive filings with the U.S. Patent and Trademark Office. (Click here for more

You may also be interested in...

Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Krka Responds To Romanian Allegations

Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts